CSIMarket
 


Voyager Therapeutics Inc   (VYGR)
Other Ticker:  
 

Cumulative Voyager Therapeutics Inc 's Leverage Ratio for Trailing Twelve Months Period

VYGR's Leverage Ratio for Trailing Twelve Months Period and Total Liabilities, Equity growth


Select the Comparisons : Select the Ratio:

VYGR Leverage Ratio for Trailing Twelve Months Period

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Equity Growth 300.41 % 120.76 % 231.42 % 185.73 % -37.91 %
Y / Y Total Liabilities Growth 15.1 % -5.93 % -0.62 % -34.14 % -39.14 %
Leverage Ratio for Trailing Twelve Months Period 0.17 0.21 0.25 0.34 0.58
Total Ranking # 627 # 1286 # 1532 # 2029 # 3105
Seq. Equity Growth 34.11 % -11.46 % -8.27 % 267.61 % -26.06 %
Seq. Total Liabilities Growth 9.29 % 8.62 % -3.8 % 0.79 % -10.68 %


Leverage Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Dec 31 2023
On the trailing twelve months basis Despite net new borrowings of 9.29% Voyager Therapeutics Inc managed to decrease Leverage Ratio for Trailing Twelve Months Period in IV. Quarter to 0.17, below Voyager Therapeutics Inc 's average Leverage Ratio for Trailing Twelve Months Period.
Leverage Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies in Biotechnology & Pharmaceuticals industry 10 other companies have achieved lower Leverage Ratio for Trailing Twelve Months Period than Voyager Therapeutics Inc . While total ranking remained unchanged compare to previous quarter at no. .

What is Leverage Ratio?
Who are VYGR's Customers?
Leverage Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 11
Sector # 70
S&P 500 # 161


Leverage Ratio for Trailing Twelve Months Period Statistics
High Average Low
2.71 1.46 0.47
(Jun 30 2020)   (Dec 31 2017)




Companies with similar average Leverage Ratio for Trailing Twelve Months Period for 12 months ending Dec 31 2023, within Biotechnology & Pharmaceuticals Industry Leverage Ratio for Trailing Twelve Months Period
Senti Biosciences Inc   0.47 
Surface Oncology Inc   0.47 
Gritstone Bio Inc   0.46 
Vaxart Inc   0.46 
Aligos Therapeutics Inc   0.46 
Recursion Pharmaceuticals Inc   0.44 
Editas Medicine Inc   0.43 
Tscan Therapeutics Inc   0.43 
Neurocrine Biosciences Inc   0.42 
Genfit S a   0.42 
Inmune Bio Inc   0.41 
Polarityte Inc   0.41 
Cellectis S a   0.40 
Bluebird Bio Inc   0.39 
Pharmacyte Biotech Inc   0.38 
Moderna Inc   0.35 
Black Diamond Therapeutics Inc   0.34 
Scholar Rock Holding Corp  0.34 
Mesoblast Ltd  0.33 
Miromatrix Medical inc   0.33 
Fusion Pharmaceuticals Inc   0.32 
Sophia Genetics Sa  0.32 
Seagen Inc   0.31 
Instil Bio Inc   0.30 
Repligen Corp  0.29 
Monte Rosa Therapeutics Inc   0.29 
Vir Biotechnology Inc   0.29 
Cognition Therapeutics inc   0.28 
Passage Bio inc   0.27 
Denali Therapeutics Inc   0.26 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com